trending Market Intelligence /marketintelligence/en/news-insights/trending/efghkn1g64vrmjmdje9nog2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us
In This List

Portola Pharmaceuticals chief commercial/business officer resigns

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Portola Pharmaceuticals chief commercial/business officer resigns

Portola Pharmaceuticals Inc. said Tao Fu resigned as executive vice president and chief commercial and business officer, effective Sept. 21, to pursue other opportunities.

South San Francisco, Calif.-based Portola said that Interim co-President and CFO Mardi Dier will lead its commercial activities, including the ongoing launches of blood disorder therapies Andexxa and Bevyxxa.

Fu will remain as a consultant until March 1, 2019, to assist in the transition.

The company said in a Sept. 7 news release that it has hired an executive search firm for recruiting a new CEO and chief commercial officer. Portola's CEO retired in August.

Portola is a biopharmaceutical company that develops and commercializes therapeutics relating to blood clotting and other blood disorders.